Boosting Drug Named Entity Recognition Using an Aggregate Classifier

I Korkontzelos, D Piliouras, AW Dowsey, S Ananiadou

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Objective

    Drug named entity recognition (NER) is a critical step for complex biomedical NLP tasks such as the extraction of pharmacogenomic, pharmacodynamic and pharmacokinetic parameters. Large quantities of high quality training data are almost always a prerequisite for employing supervised machine-learning techniques to achieve high classification performance. However, the human labour needed to produce and maintain such resources is a significant limitation. In this study, we improve the performance of drug NER without relying exclusively on manual annotations.

    Methods

    We perform drug NER using either a small gold-standard corpus (120 abstracts) or no corpus at all. In our approach, we develop a voting system to combine a number of heterogeneous models, based on dictionary knowledge, gold-standard corpora and silver annotations, to enhance performance. To improve recall, we employed genetic programming to evolve 11 regular-expression patterns that capture common drug suffixes and used them as an extra means for recognition.
    Materials

    Our approach uses a dictionary of drug names, i.e. DrugBank, a small manually annotated corpus, i.e. the pharmacokinetic corpus, and a part of the UKPMC database, as raw biomedical text. Gold-standard and silver annotated data are used to train maximum entropy and multinomial logistic regression classifiers.

    Results

    Aggregating drug NER methods, based on gold-standard annotations, dictionary knowledge and patterns, improved the performance on models trained on gold-standard annotations, only, achieving a maximum F-score of 95%. In addition, combining models trained on silver annotations, dictionary knowledge and patterns are shown to achieve comparable performance to models trained exclusively on gold-standard data. The main reason appears to be the morphological similarities shared among drug names.
    Conclusion

    We conclude that gold-standard data are not a hard requirement for drug NER. Combining heterogeneous models build on dictionary knowledge can achieve similar or comparable classification performance with that of the best performing model trained on gold-standard annotations.
    Original languageEnglish
    Pages (from-to)145–153
    Number of pages9
    JournalArtificial Intelligence in Medicine
    Volume65
    Issue number2
    DOIs
    Publication statusPublished - Oct 2015

    Fingerprint

    Dive into the research topics of 'Boosting Drug Named Entity Recognition Using an Aggregate Classifier'. Together they form a unique fingerprint.

    Cite this